|
|
News Breaks
|
January 17, 2012
|
| 08:03 EDT |  | CLDX |
| theflyonthewall.com: | Celldex initiates Phase 1 trial of CDX-301 | | Celldex Therapeutics announced that dosing has initiated in a Phase 1 study of its hematopoietic growth factor, CDX-301, in healthy subjects. The study is being conducted in collaboration with Rockefeller University. The trial will evaluate seven different dosing regimens of CDX-301 and will accrue approximately 30 healthy subjects at Rockefeller University. CDX-301 is soluble, recombinant human FMS-like tyrosine kinase 3 ligand and previous experience has shown that it increases the numbers and activity of blood stem cells and immune cells. :theflyonthewall.com |
|
|
News For CLDX From The Last 14 Days Check below for free stories on CLDX the last two weeks.
There are 6 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 24, 2012
|
| 09:13 EDT |  | CLDX |
| | 09:00 EDT | | CLDX |
| | 07:52 EDT |  | CLDX |
| theflyonthewall.com: | Celldex data not negative, says Oppenheimer | | Oppenheimer believes that data released by Celldex showed that the company's CDX-011 drug benefited patients with a large amount of cancerous cells, as it's designed to do. The firm doesn't view the lack of response in other patients as negative for the company and it maintains a $6 target and Outperform rating on the stock. :theflyonthewall.com |
|
|
May 23, 2012
|
| 16:03 EDT | | CLDX |
| theflyonthewall.com: | Celldex's CDX-011 demonstrates high response rates in patients | | Celldex Therapeutics announced preliminary results from the company's randomized Phase 2b EMERGE study of CDX-011 antibody drug conjugate in patients with glycoprotein NMB expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression. In this high expressing patient population, treatment with CDX-011 resulted in a 32% overall response rate, whereas treatment with Investigator's Choice single-agent chemotherapy resulted in a 13% ORR. CDX-011 also demonstrated strong response rates in patients with triple negative breast cancer across all levels of GPNMB expression, where treatment options are extremely limited. In addition, in patients with triple negative breast cancer who also highly express GPNMB, greater activity was observed. The ORR across all levels of GPNMB expression was 19% for the CDX-011 arm and 14% for the IC arm, and a direct, positive correlation was observed between increasing levels of GPNMB expression and increased CDX-011 response rates. Based on these data, the Company believes CDX-011 has significant promise as a targeted therapy for patients with breast cancer and high expression of GPNMB, and especially for those with triple negative disease. :theflyonthewall.com |
|
|
May 21, 2012
|
| 12:03 EDT |  | CLDX |
| theflyonthewall.com: | Celldex volatility elevated into topline results of the Phase 2b EMERGE study |
 Subscribe for More Information :theflyonthewall.com |
|
|
May 18, 2012
|
| 10:39 EDT |  | CLDX |
| theflyonthewall.com: | Celldex to host conference call | | Conference call to discuss topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer will be held on May 23 at 4:30 pm. Webcast Link :theflyonthewall.com |
|
|
|
|
|
